Shandong Jincheng Pharmaceutical Group Co Ltd operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Jincheng Pharmaceutical Group Co Ltd with three other companies in this sector in China: Shenzhen Hepalink Pharmaceutical Company Limited (2017 sales of 2.67 billion Chinese Renmimbi [US$390.28 million] of which 100% was Pharmaceutical Manufacturing), Zhejiang Jianfeng Group Company Limited (2.83 billion Chinese Renmimbi [US$413.19 million] of which 45% was Cement/Construction Materials), and Hunan ER-KANG Pharmaceutical Co Ltd (2.83 billion Chinese Renmimbi [US$413.38 million] of which 88% was Manufacture of Medicines).

Sales Analysis. During the year ended December of 2017, sales at Shandong Jincheng Pharmaceutical Group Co Ltd were 2.79 billion Chinese Renmimbi (US$407.56 million). This is an increase of 96.3% versus 2016, when the company's sales were 1.42 billion Chinese Renmimbi. This was the fifth consecutive year of sales increases at Shandong Jincheng Pharmaceutical Group Co Ltd (and since 2012, sales have increased a total of 249%). Sales of Chemical Trade saw an increase that was more than double the company's growth rate: sales were up 261.3% in 2017, from 212.89 million Chinese Renmimbi to 769.19 million Chinese Renmimbi.